clinical trial · NCT03085225
Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
Institut Bergonié·phase1·completed·n = 40
Ovarian CarcinomaSoft Tissue SarcomaCombination of trabectedin with durvalumab
brief summary
A phase Ib trial study of trabectedin when prescribed in combination with durvalumab in locally advanced/unresectable soft-tissue sarcoma and ovarian carcinomas.
started
May 5, 2017
primary completion
Nov 19, 2020
completion
Jan 4, 2022
last updated
Sep 4, 2025
detailed description
This is a multicenter, prospective phase Ib trial based on a dose escalation study design (3+3 traditional design) assessing three dose levels of Trabectedin given with durvalumab, followed by two expansion cohorts once the MTD is established.
official title
Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol